Low levels of WRAP53 protein, according to C1‐antibody, were associated with factors indicating worse prognosis (larger tumor size, higher TNM stage, higher frequency of HER2‐positive and triple‐negative subtype, and histologic grade III). Here, ERBB2 is linked to neoplasm.